Limited durability of protection conferred by XBB.1.5 vaccines against Omicron-associated severe outcomes among community-dwelling adults aged >=50 years, Ontario, Canada, September 2023 to June 2024
Lee, N.; Nguygen, L.; Nasreen, S.; Austin, P. C.; Brown, K. A.; Buchan, S. A.; Grewal, R.; Schwartz, K. L.; Tadrous, M.; Wilson, K.; Wilson, S. E.; Kwong, J. C.
Show abstract
We estimated XBB.1.5 vaccine effectiveness against hospitalization/death among adults aged [≥]50 years. Compared with non-XBB.1.5 vaccinees, the initial protection of 64% (95%CI, 57%-69%) was reduced when JN/KP-sublineages became predominant, and quickly declined. No significant protection was observed >6 months post-vaccination. Short durability of protection poses unique challenges for COVID-19 vaccination.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 98%
- Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada 96%
- Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) 96%
Similar papers in this journal
- Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination 95%
- Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong 94%
- Initial protection against Omicron in children and adolescents by BNT162b2 94%
Similar papers in this journal
- Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France 96%
- Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting 95%
- Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥65 years in the United States 94%
Similar papers in this journal
- Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial 93%
- Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults 93%
- Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.